Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Study Identifier
206207-016
CT.gov Identifier
NCT00511706
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Eye Disease
  • Macular Degeneration - Other
    • Study Drug
  • dexamethasone
  • ranibizumab
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    50+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * 50 years of age or older with subfoveal choroidal neovascularization (CNV) (classic and/or occult) secondary to AMD * Visual Acuity between 20/40 and 20/400 in the study eye
    Exclusion Criteria:
    * Any intraocular surgery within 3 months * Glaucoma * Cataract * High eye pressure * Uncontrolled systemic disease

    Protocol Summary

    The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

    Study Locations

    Location
    Status
    Location
    Boynton Beach, Florida, United States
    Status
    Not applicable
    Location
    Parramatta, New South Wales, Australia
    Status
    Not applicable
    Location
    Paris, France
    Status
    Not applicable
    Location
    Tel Aviv, Israel
    Status
    Not applicable
    Location
    Milan, Italy
    Status
    Not applicable
    Location
    Auckland, New Zealand
    Status
    Not applicable
    Showing {first} - {last} of {total} Results